Selective inhibitors of XPO1 have been shown to possess antileukemic and proapoptotic activity in AML blasts by disrupting aberrant removal of tumor suppressor proteins from the nucleus, such as TP53 [7]. The gene discussed is TP53; the disease is acute myeloid leukemia.